Developer and supplier of drug delivery systems Unilife announced last week the signing of a worldwide, 10-year commercial supply agreement with a global pharmaceutical company for the use of its Depot-ject with an ocular injection therapy.
Australian regenerative medicine company Orthocell and Scandinavian med tech BoneSupport will work together to combine their existing products into a new bone repair product. The pair hopes to further tap into the global bone graft and substitutes market, which the companies said was $2.1 billion last year and is expected to be $2.7 billion by 2020.
Amgen and Merck have launched an early-stage trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer.
With its designs on AstraZeneca at least temporarily abandoned, Pfizer has set out to create an immuno-oncology portfolio of its own, signing a deal with a Belgian biotech to get its hands on treatments that promise to sharpen the body's anticancer weaponry.
Pfizer is the latest pharma heavyweight to get behind the promise of gene therapy, as the New York drugmaker has laid out plans to set up a dedicated R&D operation and signed a deal with startup Spark Therapeutics to kick-start the effort.
BlackBerry, maker of the Passport smartphone, and health analytics company NantHealth said they will launch a clinical genome browser early next year that will be HIPAA-compliant.
INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.
Catalent has signed a deal with Sellas to help the Swiss drugmaker develop an existing insomnia treatment for other central nervous system disorders.
Meda, a Swedish specialty pharma outfit, is scaling back its relationship with contract drug developer Recipharm, endangering jobs and putting a site at risk of closure.
Point-of-care diagnostics company Welch Allyn and visual electrophysiology player LKC Technologies have signed an exclusive partnership for the former to distribute the latter's RETeval DR device, which screens for diabetic retinopathy.